CTOs on the Move

ImmunoPrecise Antibodies

www.ipatherapeutics.com

 
IPA is a progressive, scientific Contract Research Organization (CRO) recently ranked by one of the pharmaceutical industry`s most trusted, independent market research sources with the highest competitive score, for its antibody service portfolio.1 The company represents a HUB of biotherapeutic intelligence that includes a hybrid of experts and technologies, in the science and business of bioplatform-based discovery. We provide highly specialized full-continuum therapeutic antibody discovery, development, and out-licensing services [Talem] —with advanced omics and complex intelligence technology [LENSai] that provide greater efficiency and accuracy than ever before. Our mission is to provide our pharmaceutical customers with a HUB of the ...
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million

Executives

Name Title Contact Details

Funding

ImmunoPrecise Antibodies raised $21.7M on 02/03/2021

Similar Companies

Biothera

Biothera is a Saint Paul, MN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Quad Five Materials Bio

Quad Five Materials Bio is a Ryegate, MT-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Quad Five Materials Bio

Quad Five Materials Bio, Inc. is a Ryegate, MT-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Oxford Immunotec

Oxford Immunotec is a global, commercial-stage diagnostics company committed to improving patient care by providing advanced, innovative tests in the field of immunology. Our proprietary   T-SPOT technology platform allows us to measure the responses of specific immune cells, known as T cells, to inform the diagnosis, prognosis and monitoring of patients with immunologically controlled diseases.   The initial product we have developed using our T-SPOT technology platform is our T-SPOT.TB test, which is used to test for latent Tuberculosis (TB) infection, or LTBI. Our T-SPOT.TB test has been approved for sale in over 50 countries, including the United States, where we have received pre-market approval (PMA) from the Food and Drug Administration (FDA), in Europe, where we have obtained a CE mark, as well as Japan and China. Our T-SPOT.TB test has been included in clinical guidelines (that is, guidelines issued by governmental agencies and professional societies covering recommended or suggested uses of available diagnostics) for TB screening in 17 countries, including the United States, several European countries and Japan.   We are a publicly traded company listed in the United States on the NASDAQ stock exchange (NASDAQ:OXFD).

Scorpion Therapeutics

Scorpion Therapeutics was founded to expand the reach of precision medicine to more people with cancer.